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Killer immunoglobulin-like receptor 
genotype did not correlate with 
response to anti-PD-1 antibody 
treatment in a Japanese cohort
Yoshihiro Ishida  1, Chisa Nakashima1, Hiroto Kojima2, Hidenori Tanaka2, Taku Fujimura3, 
Shigeto Matsushita4, Yuki Yamamoto5, Koji Yoshino6, Yasuhiro Fujisawa7, Atsushi Otsuka1,8 & 
Kenji Kabashima1
Immune checkpoint blockade (ICB) induces a remarkable response in patients with certain cancers. 
However, the response rate is not yet satisfactory. Biomarkers that help physicians identify patients 
who would benefit from ICB need to be developed. Killer immunoglobulin-like receptors (KIRs) are a 
class of receptors that are mainly expressed by natural killer cells. KIR genotypes have been shown to 
influence the outcomes of patients with neuroblastoma and hematopoietic malignancies. KIRs may 
thus influence the clinical outcomes of melanoma patients receiving nivolumab. We aimed to identify 
the KIR genotype, or KIR/KIR-ligand combinations, which influence the outcomes of melanoma patients 
receiving nivolumab. We genotyped 112 melanoma patients who were treated with nivolumab for KIR 
and human leukocyte antigen. The clinical records of the patients were analyzed to determine if they 
showed a response to nivolumab, and whether or not they experienced adverse events. Our analysis 
showed that no KIR gene was associated with a response to nivolumab. The KIR/KIR-ligand combination 
did not correlate with a response to nivolumab. KIR genes were not predictive of experiencing adverse 
events of grade 2 or greater. We conclude that the KIR genotype or KIR/KIR-ligand genotype do not 
show predictive value in melanoma patients receiving nivolumab.
Although immune checkpoint blockade (ICB) has revolutionized the management of malignancies, there remain 
a considerable number of patients who do not respond. There is thus a great interest in developing predictive 
biomarkers to help identify patients who would benefit from ICB. These biomarkers include serum lactate dehy-
drogenase level1, baseline lymphocyte to neutrophil ratio2, PD-L1 expression of tumor cells3, mutational load4, 
gut microbiome5, and human leukocyte antigen (HLA) allele of the host6,7.
Recently, killer immunoglobulin-like receptor (KIR) genotypes have been shown to influence clinical out-
comes in neuroblastoma patients receiving IL-2 immunotherapy or anti-GD1 antibody treatment8,9. KIRs are a 
class of regulatory molecules that are mainly expressed by natural killer (NK) cells. NK cells play a major role in 
tumor immunity, and their activation is regulated by a complex integration of inhibitory and stimulatory signals. 
Among the regulatory signals, KIRs are important for inter-individual difference in NK cell activity. KIR genes 
exhibit high allelic and haplotypic diversity, which results in variation in the NK cell repertoire among individ-
uals. In several KIR genes, KIR-ligands are identified as HLA molecules. Examples of this include KIR1DL1/
HLA-C1, KIR2DL1/HLA-C2, and KIR3DL1/HLA-Bw4. Absence/presence of the KIR/KIR–ligand pair adds fur-
ther diversity to the individual immune profile10.
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In light of the pressing need to develop biomarkers for ICB, we asked if the KIR or compound KIR–ligand 
genotype predicts the outcome of ICB by studying melanoma patients treated with nivolumab. We also asked if 
immune-related adverse events caused by ICB are associated with the KIR genotypes because they emulate auto-
immune diseases, such as interstitial pneumonia, Hashimoto’s thyroiditis, and type 1 diabetes, some of which were 
shown to be influenced by KIR genotypes11,12. We conducted a genetic association study in which 112 melanoma 
patients receiving nivolumab therapies were genotyped for KIR and HLA. In this study, we report that the KIR or 
KIR–ligand genotype does not influence the clinical outcomes of melanoma patients receiving nivolumab therapy.
Results
No KIR genotype was associated with clinical response. One hundred and twelve melanoma 
patients were enrolled. Of these, 58 were male and 54 were female. The median age was 68 years old (26–93, mini-
mum-maximum). Overall, 27.7% of patients (n = 31) showed a response to nivolumab therapy. Clinical response 
was not assessable in five patients, and they were removed in subsequent related analyses. Patient characteristics 
were similar between responders and non-responders except for disease subtype (Table 1). We noted that mucosal 
melanoma was under-represented in responders. Although not significant, the odds ratio of mucosal melanoma 
responding to the therapy was 0.684 (p-value: 0.058, 95% CI: 0.228–1.932) compared to the cutaneous subtype 
set as baseline. Melanoma subtypes were controlled for in the subsequent multivariate analysis. In both univariate 
and multivariate analysis, none of the KIR genes correlated with response to nivolumab (Table 2).
KIR/KIR-ligand combination was not associated with clinical response. Because KIR and HLA 
genes are independently inherited, a compound KIR-HLA genotype may be more predictive of the host’s 
immune profile, as shown previously13. First, we examined if the presence of matching HLA alleles was asso-
ciated with clinical response. No KIR –HLA combinations were associated with clinical response to nivolumab 
(Table 3). Among the KIR genes tested, a compound HLA-Bw4 and KIR3DL1 genotype was well characterized. 
The expression level of KIR3DL1 was predicted by the allotype. HLA-Bw4 is further classified into low- and 
high-affinity allotypes. Combining these two variables, we predicted the interaction strength between KIR3DL1 
and HLA-Bw4, as described previously14. However, the predicted interaction strength between KIR3DL1 and its 
ligands was not associated with clinical response (Table 4).
KIR genotype was not associated with adverse events. Next, we asked if a particular KIR genotype 
influenced whether or not a patient developed adverse events. Overall, our cohort showed 35 adverse events of 
grade 2 or greater. Frequent adverse events included abnormal liver function (4 patients), colitis (4 patients), 
hypothyroidism (4 patients), interstitial pneumonia (4 patients), low platelet count (3 patients), and uveitis (3 
patients). None of the adverse effect categories had a sufficient number of patients to be analyzed meaningfully. 
We analyzed if a patient developed any “significant” adverse events, defined as adverse events of grade 2 or greater. 
Individuals with KIR2DL2 seem to be more likely to experience adverse events, with a crude p-value of 0.0461 and 
an odds ratio of 3.4 (95% CI: 1.04–11.1) (Table 5). We then adjusted the p-values using the Benjamin-Hochberg 
procedure. The adjusted p-value for KIR2DL2 was 0.34.
Discussion
Despite the recognized role of NK cells in cancer immunology, our study does not demonstrate that the KIR 
genotype correlates with clinical outcomes in nivolumab therapy. A previous study showed that the KIR genotype 
was associated with the development, progression, and metastasis of melanoma15. Our study, however, suggests 
that KIR is not a major determinant in discriminating responders from non-responders in melanoma patients 
receiving anti-PD-1 therapy. In our cohort, the KIR genotype does not appear to affect whether or not a patient 
experiences adverse events.
Responder 
(n = 31)
Non-responder 
(n = 76)
Age - median (min - max) 68 (27–89) 66 (26–93)
Sex
  Female 15 37
  Male 16 39
RECIST category
CR 7 SD 19
PR 17 PD 57
dSD 7
Disease subtypes
  Cutaneous 12 (26.1%) 34 (73.9%)
  Mucosal 7 (19.4%) 29 (80.6%)
  Acral 8 (44.4%) 10 (55.6%)
  Uveal 2 (40.0%) 3 (60%)
  Unknown 2 (100%)
Table 1. Patient characteristics and clinical response. RECIST: response evaluation criteria in solid tumors, CR: 
complete response, PR: partial response, dSD: durable stable disease, SD: stable disease, PD: progressive disease.
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Our results are inconclusive in terms of whether the action of anti-PD-1 therapy is dependent on NK cells. 
The action of anti-PD-1 therapy may depend solely on CD8+ T cells and not on NK cells. Mounting evidence, 
however, shows that NK cells play a part in regulating the tumor microenvironment. One recent report showed 
that, in melanoma patients, NK cells recruit conventional DCs to the tumor microenvironment and augment 
anti-tumor immunity16. It is more likely that NK cells play a role in tumor immunity, but the success of anti-PD-1 
therapy is dependent on factors other than KIRs. We speculate that the KIR genotype may prove important for 
melanoma patients in different contexts, and that the KIR genotype may affect the outcome of anti-CTLA4 treat-
ment or NK cell adoptive transfer therapies. KIR genotyping in these contexts would merit consideration.
Predicting adverse events caused by ICB is of great interest. However, our research results show that the 
KIR genotype does not have predictive value in respect to developing adverse events. In our dataset, KIR2DL2 
appeared to confer a risk of developing adverse events. Correction for multiple testing declined the significance of 
KIR2DL2. Previous reports on predicting adverse events include the clonal expansion of CD8+ cells in circula-
tion17, or the diversification of the T-cell repertoire18. It is likely that CD8+ T cells, but not NK cells, mediate the 
adverse events caused by ICB.
KIR gene
KIR Present KIR Absent Univariate Multivariate
p-value
Odds ratio 
(95% CI)
Responders/
total (rate)
Responders/
total (rate) p-value
Odds ratio 
(95% CI)
2DL1 31/112 (0.28) 0/0 (NA) NA NA 0.36 NA
2DL2 6/14 (0.43) 25/98 (0.26) 0.23 2 (0.62–6.5) 0.26 2.4 (0.71–8.1)
2DL3 31/111 (0.28) 0/1 (0) 0.99 NA 0.15 NA
2DL4 31/112 (0.28) 0/0 (NA) NA NA 0.42 NA
2DL5 11/41 (0.27) 20/71 (0.28) 0.89 0.94 (0.39–2.2) 0.71 1.2 (0.46–3)
2DS1 11/39 (0.28) 20/73 (0.27) 0.9 1.1 (0.43–2.5) 0.73 1.3 (0.5–3.3)
2DS2 7/15 (0.47) 24/97 (0.25) 0.11 2.5 (0.79–7.6) 0.15 3.1 (0.96–10)
2DS4 31/108 (0.29) 0/4 (0) 0.99 NA 0.56 NA
2DS3 5/15 (0.33) 26/97 (0.27) 0.55 1.4 (0.41–4.6) 0.38 1.7 (0.46–5.6)
2DS5 7/30 (0.23) 24/82 (0.29) 0.5 0.72 (0.26–1.8) 0.37 0.85 (0.29–2.3)
2DS3/5 11/41 (0.27) 20/71 (0.28) 0.89 0.94 (0.39–2.2) 0.71 1.2 (0.46–3)
3DL1 31/108 (0.29) 0/4 (0) 0.99 NA 0.56 NA
3DS1 10/39 (0.26) 21/73 (0.29) 0.75 0.86 (0.35–2.1) 0.89 1.1 (0.4–2.7)
3DL2 31/112 (0.28) 0/0 (NA) NA NA 1 NA
3DL3 31/112 (0.28) 0/0 (NA) NA NA 0.99 NA
Table 2. KIR genotype and clinical response. Presence of each KIR genotypes is analyzed for correlation with 
clinical response using logistic regression models. In multivariate analysis, melanoma subtypes and KIR genes 
are included in the model. NA denotes that the model did not converge.
HLA epitope/KIR gene
Interaction No interaction
p-value
Odds ratio  
(95% CI)
Responders/total 
(rate)
Responders/total 
(rate)
HLA-Bw4/KIR3DL1 25/89 (0.28) 6/18 (0.33) 0.78 0.78 (0.25–2.4)
HLA-C1/KIR2DL2 6/13 (0.46) 25/94 (0.27) 0.19 2.3 (0.68–7.8)
HLA-C1/KIR2DL3 30/104 (0.29) 1/3 (0.33) 1.00 0.81 (0.062–24)
HLA-C2/KIR2DL1 6/15 (0.4) 25/92 (0.27) 0.36 1.8 (0.55–5.6)
Table 3. KIR–KIR ligand interaction and clinical response. All patients were assessed for presence of each KIR 
gene/KIR ligand pair. Fisher’s exact test was used to estimate p-values and odds ratio.
Interaction 
strength
Univariate Multivariate
Odds ratio (95% 
CI) p-value
Odds ratio 
(95% CI)
Responders/total 
(rate) p-value
No 6/22 (0.27) NA NA NA NA
Weak 11/42 (0.26) 0.79 1.1 (0.51–2.6) 0.74 1.2 (0.5–2.9)
Strong 14/47 (0.3) 0.72 1.1 (0.55–2.4) 0.95 1 (0.48–2.2)
Table 4. Predicted interaction strength between KIR3DL1 and HLA-Bw4 and clinical response. HLA-Bw4 
epitopes are classified into high affinity, low affinity or absent. KIR3DL1 expression was estimated from the KIR 
allotypes. Strength of the interaction between KIR3DL1 and its ligand interaction was predicted based on these 
results and then was analyzed for correlation with clinical response. ‘No interaction’ group was set as baseline.
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There are several limitations in this study. First, patients were enrolled from regular clinical practices from 
multiple hospitals. This study design precludes the uniformity of study participants and evaluation criteria. For 
example, our ad hoc analysis showed considerable variation in patient characteristics among participating hos-
pitals. A multivariate analysis controlling for hospitals did not show any correlation between KIR genotype and 
clinical outcomes (data not shown). Nevertheless, we cannot confidently exclude the possibility that there may be 
unmeasurable biases at play in this study group.
Second, our study is confined to the Japanese population. KIR genotypes are highly variable among eth-
nic groups19. One cannot necessarily assert that our findings would apply to other countries or ethnic groups. 
Moreover, acral/mucosal melanoma is overrepresented in Japan as compared to Western countries, where cuta-
neous melanomas predominate20. Such discrepancy in melanoma subtypes may further complicate the interpre-
tation of our results. Considering the total absence of possible associations in our study, however, the chance of 
identifying a clinically relevant KIR genotype in other ethnic groups would be slim.
Third, adverse events grade 2 or greater are documented only in 35 cases out of 112 patients analyzed. Our 
study may be underpowered to conclusively decline associations between KIR genotypes and adverse events.
Lastly, our study is focused solely on KIR and KIR-HLA compound genotypes. This study design overlooks 
the possibilities that polymorphisms in other genes may influence the response to cancer immunotherapy in 
melanoma patients.
In conclusion, our genetic association study did not detect an association between KIR genotype and clinical 
outcomes of nivolumab treatment in a Japanese cohort. Further studies on KIR genotype and cancer should focus 
on other treatment modalities, such as anti-CTLA4 treatment or NK cell therapy.
Methods
Patients. We enrolled melanoma patients who were treated with nivolumab at participating hospitals in Japan 
between July 2014 and October 2017. Patients who had follow-up periods less than 3 months after the initiation 
of nivolumab treatment were excluded from the study. This study was approved by the institutional review board 
at Kyoto university (G1014). Written informed consent was obtained from all participants. The study was carried 
out according to the approved protocol.
HLA and KIR genotyping. DNA was extracted from the patients’ blood using a QuickGene DNA whole 
blood kit S (Kurabo, Osaka, Japan). Genotyping was performed at HLA Laboratory (Kyoto, Japan). Briefly, a 
DNA library was prepared using IGS-HLA version 4.0 and IGS-KIR version 2.1 typing kits (Scisco Genetics, 
Inc., Seattle, WA) according to the manufacturer’s protocol. The library was sequenced on the MiSeq platform 
(Illumina, San Diego, CA).
KIR–ligand analysis. In analyzing the interaction between the HLA allele and KIR genes, each patient was 
evaluated for KIR3DL1, KIR2DL1, and KIR2DL2/3. A patient was considered to carry a KIR gene if the patient 
had at least one copy of the gene. Next, using a table extracted from Marra et al.13, HLA alleles were assigned to 
KIR-ligands, and then the absence or presence of KIR–ligand combination was determined.
The interaction between HLA-B alleles and KIR3DL1 allelic polymorphism was analyzed according to the 
previously described procedure9. Briefly, HLA-B alleles were assigned to HLA-Bw4-80I, HLA-Bw4-80T, or Bw6 
using the immune polymorphism database21, and then each patient was categorized according to compound 
KIR gene
KIR gene present KIR gene absent
Patients with adverse 
events/total (rate)
Patients with adverse 
events/total (rate)
p-value 
(crude)
p-value 
(adjusted)
Odds ratio 
(95% CI)
2DL1 29/112 (0.26) 0/0 (NA) NA NA NA
2DL2 7/14 (0.5) 22/98 (0.22) 0.046* 0.34 3.4 (1–11)
2DL3 28/111 (0.25) 1/1 (1) 0.26 0.70 0 (0–6.6)
2DL4 29/112 (0.26) 0/0 (NA) NA NA NA
2DL5 10/41 (0.24) 19/71 (0.27) 0.83 0.83 0.88 (0.35– 2.2)
2DS1 8/39 (0.21) 21/73 (0.29) 0.38 0.70 0.64 (0.25–1.6)
2DS2 7/15 (0.47) 22/97 (0.23) 0.061 0.34 2.9 (0.92–9.9)
2DS4 29/108 (0.27) 0/4 (0) 0.57 0.70 Inf (0.31–Inf)
2DS3 5/15 (0.33) 24/97 (0.25) 0.53 0.70 1.5 (0.46–4.8)
2DS5 6/30 (0.2) 23/82 (0.28) 0.47 0.70 0.64 (0.23–1.8)
2DS3/5 10/41 (0.24) 19/71 (0.27) 0.83 0.83 0.88 (0.35–2.2)
3DL1 29/108 (0.27) 0/4 (0) 0.57 0.70 Inf (0.31–Inf)
3DS1 8/39 (0.21) 21/73 (0.29) 0.38 0.70 0.64 (0.25–1.6)
3DL2 29/112 (0.26) 0/0 (NA) NA NA NA
3DL3 29/112 (0.26) 0/0 (NA) NA NA NA
Table 5. Correlation of KIR genes with adverse events grade 2 or greater. Presence of each KIR gene is analyzed 
for correlation with developing adverse events CTCAE grade 2 or greater. The table shows both crude p-values 
and p-valued adjusted using Benjamini-Hochberg procedure. * < 0.05, NA: value was not meaningfully 
calculated, Inf: infinite number.
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epitopes. KIR3DL1 alleles were classified into functional subtypes according to the previous publication22. 
Compound HLA-B epitope and KIR3Dl1 subtypes were combined to predict the strength of interaction between 
KIR3DL1 and HLA-B ligands.
Statistical analysis. We used response evaluation criteria in solid tumors (RECIST) 1.1 to assess clinical 
response. Response was defined as complete response, partial response, or stable disease lasting more than 6 
months. We used common terminology criteria for adverse events (CTCAE) version 4.0 to evaluate adverse 
events. Significant adverse events were defined as those of grade 2 or greater. The logistic regression model was 
used to estimate the odds ratio and 95% confidence interval (CI) in evaluating the association of KIR genotypes 
and KIR–ligand combination with clinical response. In multivariate analysis, age, sex, and tumor subtypes were 
initially screened for potential association with clinical outcomes, and those with significant associations were 
then used in the final analysis. Fisher’s exact test was used in the remaining analyses. Considering the exploratory 
nature of this study, correction for multiple testing was not performed initially. When an analysis yielded a p-value 
smaller than 0.05, adjusted p-values were computed using the Benjamin-Hochberg procedure. A p-value < 0.05 
was considered statistically significant. All statistical analyses were carried out with R software (version 3.4.3, R 
core team, Vienna, Austria). Two-sided Fisher’s exact test was performed as instructed in the exact2x2 package23.
The datasets generated from the current study is included in the article and its Supplementary Information 
Material.
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